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Abstract
The magnitude of treatment effect can be assessed by a number of methods. One reliable method of collectively
analysing data from randomised clinical trials is that used in Cochrane reviews. These systematic reviews identify
and analyse the available evidence using the reliable method of meta-analysis. These often combine data from
studies to provide robust evaluations of overall treatment effects. In 2003, a review of data from studies of
corticosteroid use in IPF patients found no evidence of a treatment effect. Similarly, very little evidence was found
to support the use of immunomodulatory agents. A recent update of these Cochrane reviews failed to identify any
new evidence supporting the use of corticosteroids in IPF. However, a review of non-steroid agents for the
treatment of IPF identified data from 15 RCTs that was suitable for analysis. Two trials of interferon gamma-1b were
pooled and analysed, but no treatment effect was observed in terms of survival. Meta-analysis of three Phase III
studies of pirfenidone treatment in IPF patients suggested that progression-free survival was significantly increased
by 30%, demonstrating a reduction in the decline of lung function in IPF patients. In addition, there are numerous
ongoing trials investigating potential therapeutic agents which provides hope for IPF patients and their doctors.
Introduction
It is clear that treatment decisions and the clinical man-
agement of patients with idiopathic pulmonary fibrosis
(IPF) should be based primarily on the findings of rando-
mised controlled trials, and also, to a certain extent,
expert opinion. Since 2004 there has been an increase in
the number of clinical trials investigating the treatment
of IPF, with 13 randomised clinical trials (RCT) designed
and completed during the last eight years. These trials
included the use of nine different potential drugs, and are
encouraging in terms of the research effort focusing on
trying to find an effective treatment for this disease. As
the number of clinical trials completed increases, the
question then is how best to analyse the data from these
studies to determine a treatment effect.
The Cochrane meta-analysis
There are numerous ways to analyse data, and one of
these is the systematic evaluation of available data. This
process was pioneered by Cochrane in the 1970s, who
stressed the importance of using data from randomised,
controlled trials as these are likely to provide more
reliable evidence than other sources. The “Cochrane
Collaboration” was subsequently established, with the
aim of analysing existing data on various treatment
effects. The systematic reviews are published in the
Cochrane Library and identify and appraise the available
evidence in a treatment area, using the powerful method
of meta-analysis [1]. Cochrane reviews are based on a
systematic analysis of all published data, for a given treat-
ment. The identification of data for inclusion in a specific
meta-analysis is based on predefined criteria. The statisti-
cal approach of meta-analysis allows combining of data
from relevant clinical trials and thus provides precise
estimates of the effects of a given treatment in a specific
patient population. Meta-analyses are typically conducted
on a single study endpoint and graphically depicted as
“forest plots” [2], which show the effect of different stu-
dies on the given endpoint.
A key example of the importance of meta-analyses is
that published by Antman et al. (1992) [3] on the effects
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of oral b-blockers for the secondary prevention of mortal-
ity in patients surviving a myocardial infarction. This
study showed that a number of trials on this specific topic
were performed without need, as a prior meta-analysis
would have determined the benefit of b-blockers in treat-
ing heart failure patients, therefore avoiding the need for
numerous placebo-controlled trials that were subsequently
performed, exposing patients to treatment with placebo
rather than an active treatment.
Cochrane meta-analyses in IPF treatment
In 2000 the American Thoracic Society (ATS) and Eur-
opean Respiratory Society (ERS) published an interna-
tional consensus statement with guidelines for the
diagnosis and treatment of IPF [4]. This recommended
that patients with IPF should be treated with a combined
therapy of corticosteroids and an immunosuppressive
agent (e.g. azathioprine or cyclophosphamide) until ade-
quate studies had been performed to define the best treat-
ment for IPF. Three years later, we conducted a Cochrane
review of the use of corticosteroids in IPF [5]. This analysis
showed that there were no existing placebo-controlled
clinical trials that had assessed the efficacy of corticoster-
oid therapy in IPF patients. Therefore, no existing
evidence supported the efficacy of corticosteroids for in
the treatment of IPF patients.
We then did the same review on the use of immunomo-
dulatory agents in IPF in 2003 [6]. Four randomised, con-
trolled clinical studies were suitable for a meta-analysis
[7-10]; however, these studies used four different immuno-
suppressive agents (cyclophosphamide, azathioprine, col-
chicine and interferon gamma-1b) and so a meta-analysis
was not possible. The authors concluded that there was
little evidence to justify the routine use of any immuno-
suppressive agent (or in fact any non-corticosteroid agent)
in the management of IPF at that time.
In 2010, the Cochrane meta-analysis on the use of cor-
ticosteroids for IPF was updated [11]. However, seven
years after the publication of the first Cochrane review
on the use of corticosteroids in IPF, there was still no evi-
dence to support the efficacy of corticosteroids in the
management of IPF, but there was also no evidence to
rule out the use of corticosteroids in IPF [11]. Therefore
clinicians were left with continued uncertainty over the
use of these agents in IPF. Since 2003, no placebo-con-
trolled trials of corticosteroids in IPF had been underta-
ken, probably due to the fact that there was simply no
previous clear evidence to show that they were, or were
not, an effective treatment option. However, the recent
PANTHER-IPF Study has suggested that there was an
increased risk of death and hospitalizations in patients
with IPF who were treated with a combination of predni-
sone, azathioprine, and NAC, as compared with placebo
[12].
In 2010, a systematic search was conducted to identify
RCT that investigated the use of non-steroid agents for
the treatment of IPF. This then became the subject of a
further Cochrane Review [13]. This systematic search
found that, in 2010, thirteen RCT could be included.
Contact with pharmaceutical companies and fellow
researchers led to the identification of two other suitable
clinical trials which would have been published soon after
the timing of the analysis, allowing their inclusion. The
analysis of endpoints and quality of the methodology of
these fifteen trials reduced the number to seven that were
eligible for meta-analyses: only the antifibrotic agents
interferon gamma-1b and pirfenidone were evaluated in
more than one trial and, therefore, were potentially eligible
for two separate meta-analyses.
Combining the data from the two RCT on interferon
gamma-1b [14,15] in a meta-analysis, using the clinical
endpoint of overall survival, showed that there were no
statistically significant differences in mortality between
interferon gamma-1b and placebo. Interestingly, the larger
of the two trials, published by King et al., was negative for
efficacy in terms of the overall survival endpoint [14],
whereas the smaller trial almost demonstrated statistical
significance [15].
For the treatment effect of pirfenidone, the three clinical
trials that were eligible for analysis, i.e. the two large, inter-
national, randomized CAPACITY (004 and 006) trials [16]
and the Japanese SP3 trial,[17] did not have a common
primary endpoint (FVC and VC, respectively). However,
the identification of data for inclusion in a specific
Cochrane meta-analysis is based on pre-defined criteria.
Progression-free survival (PFS) data, defined as either
death or 10% decrease in FVC, was used as a secondary
endpoint in the CAPACITY studies and the Japanese
study published by Taniguchi et al.[17] Definitive evidence
of clinical efficacy in a Phase 3 trial is best shown by a
beneficial impact on a clinically meaningful endpoint—
that is, an endpoint that directly measures how a patient
feels (symptoms), functions (the ability to perform activ-
ities in daily life), or survives. For patients with IPF, there
are currently no validated surrogate endpoints [18]. Never-
theless, PFS data from these studies were considered suita-
ble for a meta-analysis based on these criteria. The overall
result of this meta-analysis showed that treatment with
pirfenidone reduced the risk of disease progression by 30%
(HR 0.70, 95% CI 0.56 to 0.88; Figure 1) [13]. This high-
lights that pirfenidone is the only drug to date that has
shown a significant effect on progression free survival,
defined as either death or 10% FVC decrease, compared
with placebo in patients with IPF.
The number of clinical trials investigating treatments for
IPF is expected to continue to increase, and the use of
multiple different drugs in the treatment of IPF might be
observed in the future. There are multiple on-going trials
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investigating potential therapeutic agents acting on various
different targets. This is very encouraging for IPF patients
and doctors, in terms of the research effort focused on
finding a suitable treatment.
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